Cost-effectiveness of ustekinumab in moderate to severe Crohn’s disease in Sweden

Cost-effectiveness of ustekinumab in moderate to severe Crohn’s disease in Sweden

Abstract Background Human monoclonal antibody ustekinumab is a novel Crohn’s disease (CD) treatment blocking pro-inflammatory cytokines interleukin-12 and 23. The study’s objective was to assess cost-effectiveness of ustekinumab in moderate to severely active CD in Sweden. Methods A cost-effectivene...

Full description

Bibliographic Details
Main Authors: Amanda Hansson-Hedblom, Chrissy Almond, Fredrik Borgström, Indeg Sly, Dana Enkusson, Anders Troelsgaard Buchholt, Linda Karlsson
Format: Article
Language:English
Published: BMC 2018-08-01
Series:Cost Effectiveness and Resource Allocation
Subjects:
Crohn’s disease
Ustekinumab
Adalimumab
Vedolizumab
Cost-effectiveness
Online Access:http://link.springer.com/article/10.1186/s12962-018-0114-y

Internet

http://link.springer.com/article/10.1186/s12962-018-0114-y

Similar Items